766539-67-7

Basic information

• Product Name: 3-Furancarboxamide,tetrahydro-N-methoxy-N-methyl-(9CI)
• Synonyms: 3-Furancarboxamide,tetrahydro-N-methoxy-N-methyl-(9CI);tetrahydro-N-methoxy-N-methyl-3-Furancarboxamide;N-methoxy-N-methyltetrahydrofuran-3-carboxamide;N-Methoxy-N-methyl tetrahydro-3-furamide, tech grade
• CAS NO: 766539-67-7
• Molecular Formula: C₇H₁₃NO₃
• Molecular Weight: 159.18302
• Product Categories: AMIDE
• Mol File: 766539-67-7.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 213.3±50.0 °C(Predicted)
• Appearance: /
• Density: 1.127±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 3-Furancarboxamide,tetrahydro-N-methoxy-N-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Furancarboxamide,tetrahydro-N-methoxy-N-methyl-(9CI)(766539-67-7)
• EPA Substance Registry System: 3-Furancarboxamide,tetrahydro-N-methoxy-N-methyl-(9CI)(766539-67-7)

Safety Data

• Hazardous Substances Data: 766539-67-7(Hazardous Substances Data)

Usage

Uses

N-Methoxy-N-methyl tetrahydro-3-furamide, tech grade

Upstream product

• 89364-31-8 3-tetrahydrofuroic acid 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 488-93-7 3-Furoic acid 

Downstream Products

• 114932-86-4 1-(tetrahydrofuran-3-yl)ethanone 

Relevant articles and documents

PURINES AND METHODS OF THEIR USE

Disclosed are compounds useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases.

COMPOUNDS USEFUL AS KINASE INHIBITORS

This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK).The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.

New Enzyme Inhibitor Compounds

Disclosed are compounds which inhibit SSAO enzyme activity. Also disclosed are pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumour growth.